While Teva- Pharmaceutical Industries Ltd. ADR has overperformed by 2.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TEVA rose by 28.90%, with highs and lows ranging from $27.90 to $12.47, whereas the simple moving average jumped by 57.61% in the last 200 days.
On June 06, 2025, Goldman started tracking Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) recommending Buy. A report published by Truist on May 28, 2025, Initiated its previous ‘Buy’ rating for TEVA. JP Morgan also Upgraded TEVA shares as ‘Overweight’, setting a target price of $23 on the company’s shares in a report dated May 12, 2025. JP Morgan March 08, 2024d its ‘Underweight’ rating to ‘Neutral’ for TEVA, as published in its report on March 08, 2024. Piper Sandler’s report from February 12, 2024 suggests a price prediction of $19 for TEVA shares, giving the stock a ‘Overweight’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Further, the quarter-over-quarter increase in sales is 3.17%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Teva- Pharmaceutical Industries Ltd. ADR’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 10.77% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and TEVA is recording an average volume of 11.21M. On a monthly basis, the volatility of the stock is set at 3.26%, whereas on a weekly basis, it is put at 2.23%, with a gain of 7.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $30.00, showing growth from the present price of $28.41, which can serve as yet another indication of whether TEVA is worth investing in or should be passed over.
How Do You Analyze Teva- Pharmaceutical Industries Ltd. ADR Shares?
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is based in the Israel and is one of the most prominent companies operating in the Drug Manufacturers – Specialty & Generic market. When comparing Teva- Pharmaceutical Industries Ltd. ADR shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 46.40, there is a growth in quarterly earnings of 196.61%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.16%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 58.27% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
